Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety

Harmsen, Michiel M.; Antonis, A.F.G.; Moormann, R.J.M.; Kortekaas, Jeroen

doi:10.4161/bbug.2.1.13349

Cited by 7 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…vaccination is discussed controversially. It was reported to be successful after a single administration in calves, but inferior to a parental application in sheep [ 53 , 54 , 59 ].…”

Section: Discussionmentioning

confidence: 99%

“…The potential of NDV as a vector for the expression of heterologous proteins of other avian pathogens and as bivalent vaccine has been repeatedly shown [ 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. Additionally, the safety and the immunogenicity of NDV in mammals was demonstrated for different species [ 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ]. Due to its strong host range restriction, only minimal replication in non-host species is expected, resulting in the potential for a safe, attenuated vaccine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Recombinant Newcastle Disease Virus Vectored DIVA Vaccine against Peste des Petits Ruminants in Goats

et al. 2020

View full text Add to dashboard Cite

Peste des petits ruminants virus (PPRV, species: small ruminant morbillivirus) is the causative agent of the eponymous notifiable disease, the peste des petits ruminants (PPR) in wild and domestic sheep and goats. Mortality rates vary between 50% and 100%, causing significant losses of estimated 1.5 to 2 billion US Dollars per year. Live-attenuated PPRV vaccine strains are used in the field for disease prevention, but the application of a more thermostable vaccine enabling differentiation between infected and vaccinated animals (DIVA) would be highly desirable to achieve the goal of global disease eradication. We generated a recombinant Newcastle disease virus (rNDV) based on the live-attenuated NDV Clone 30 that expresses the surface protein hemagglutinin (H) of PPRV strain Kurdistan/11 (rNDV_HKur). In vitro analyses confirmed transgene expression as well as virus replication in avian, caprine, and ovine cells. Two consecutive subcutaneous vaccinations of German domestic goats with rNDV_HKur prevented clinical signs and hematogenic dissemination after an intranasal challenge with virulent PPRV Kurdistan/11. Virus shedding by different routes was reduced to a similar extent as after vaccination with the live-attenuated PPRV strain Nigeria 75/1. Goats that were either not vaccinated or inoculated with parental rNDV were used as controls. In summary, we demonstrate in a proof-of-concept study that an NDV vectored vaccine can protect against PPR. Furthermore, it provides DIVA-applicability and a high thermal tolerance.

show abstract

“…vaccination is discussed controversially. It was reported to be successful after a single administration in calves, but inferior to a parental application in sheep [ 53 , 54 , 59 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Novel Recombinant Newcastle Disease Virus Vectored DIVA Vaccine against Peste des Petits Ruminants in Goats

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In mammals, NDV vectored vaccines present two major advantages: first, there is no pre-existing immunity against the vector and second, the virus is not able to block the innate immune response in mammalian cells, which results in increased safety and immunogenicity. Recently, recombinant NDVs expressing the Rift Valley Fever Virus (RVFV) envelope proteins (Gn and Gc) have been shown to induce complete protection in mice and sheep [27,28].…”

Section: Replication Competent Viral Vectorsmentioning

confidence: 99%

Novel vaccine strategies against emerging viruses

Garcı́a-Sastre

Mena

2013

Current Opinion in Virology

View full text Add to dashboard Cite

One of the main public health concerns of emerging viruses is their potential introduction into and sustained circulation among populations of immunologically naïve, susceptible hosts. The induction of protective immunity through vaccination can be a powerful tool to prevent this concern by conferring protection to the population at risk. Conventional approaches to develop vaccines against emerging pathogens have significant limitations: lack of experimental tools for several emerging viruses of concern, poor immunogenicity, safety issues, or lack of cross-protection against antigenic variants. The unpredictability of the emergence of future virus threats demands the capability to rapidly develop safe, effective vaccines. We describe some recent advances in new vaccine strategies that are being explored as alternatives to classical attenuated and inactivated vaccines, and provide examples of potential novel vaccines for emerging viruses. These approaches might be applied to the control of many other emerging pathogens.

show abstract

“…route was obtained by s.c., while i.n. administration did not elicit neutralizing antibody responses in sheep (Harmsen et al, 2011). In the subsequent study, lambs vaccinated once (i.m.)…”

Section: Newcastle Disease Virus Vectorsmentioning

confidence: 99%

Novel approaches to develop Rift Valley fever vaccines

Indran

Ikegami

2012

Front. Cell. Inf. Microbio.

View full text Add to dashboard Cite

Rift Valley fever (RVF) is endemic to sub-Saharan Africa, and has spread into Madagascar, Egypt, Saudi Arabia, and Yemen. Rift Valley fever virus (RVFV) of the family Bunyaviridae, genus Phlebovirus causes hemorrhagic fever, neurological disorders or blindness in humans, and high rate abortion and fetal malformation in ruminants. RVFV is classified as a Category A Priority pathogen and overlap select agent by CDC/USDA due to its potential impact on public health and agriculture. There is a gap in the safety and immunogenicity in traditional RVF vaccines; the formalin-inactivated RVFV vaccine TSI-GSD-200 requires three doses for protection, and the live-attenuated Smithburn vaccine has a risk to cause abortion and fetal malformation in pregnant ruminants. In this review, problems of traditional vaccines and the safety and efficacy of recently reported novel RVF candidate vaccines including subunit vaccines, virus vector, and replicons are discussed.

show abstract

Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety

Cited by 7 publications

References 24 publications

A Novel Recombinant Newcastle Disease Virus Vectored DIVA Vaccine against Peste des Petits Ruminants in Goats

A Novel Recombinant Newcastle Disease Virus Vectored DIVA Vaccine against Peste des Petits Ruminants in Goats

Novel vaccine strategies against emerging viruses

Novel approaches to develop Rift Valley fever vaccines

Contact Info

Product

Resources

About